Karyopharm Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $146.1 | $145.2 | $146.0 | $157.1 | $209.8 |
| Operating income | -$90.7 | -$119.4 | -$129.5 | -$142.2 | -$98.3 |
| Net income | -$196.0 | -$76.4 | -$143.1 | -$165.3 | -$124.1 |
| Balance Sheet | |||||
| Total debt | — | — | — | — | $193.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$75.4 | -$127.6 | -$92.7 | -$149.7 | -$107.3 |
Shares outstanding 22.7M · Free float 65.6%
Annual filing data through FY ended December 31, 2025; float as of August 31, 2026.